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Testicular germ cell tumours (TGCT) provide a unique model for
correlating tumour progression with biochemical changes. While
primarily gonadal, germ cell tumours also arise occasionally from
germ cell nests remaining in the mediastinum, retroperitoneum
and midline of the brain (Goss et al, 1994). Histologically, these
tumours can be divided into two broad classes, seminoma (SE),
which comprise approximately half of these tumours, and other
histological subtypes, including embryonal carcinoma (EC),
immature and mature teratoma (IT and MT), yolk sac tumour
(YS), choriocarcinoma (CC) and mixed germ cell tumours
(MGCT). All of the above invasive and potentially metastatic
malignancies are preceded by a form of non-invasive intratubular
field disease, testicular carcinoma in situ (CIS), which invariably
progresses over a period of up to 10 years to an invasive malig-
nancy (Skakkebæk and Bertheleson, 1981; Von der Maase et al,
1986, 1987; Skakkebæk et al, 1987). Although the incidence of
TGCT peaks between the second and fourth decade (Nicholson
and Harland, 1995), the presence of shared surface markers among
primordial fetal gonocytes, CIS and TGCT, but absent in normal
adult testis, supports the speculation that the initial transforming
event leading to germ cell neoplasia occurs prenatally in a fetal
gonocyte (Skakkebæk et al, 1987; Jørgensen et al, 1995).
Specifically, fetal gonocytes, CIS and TGCT express placental
alkaline phosphatase, the c-kitproto-oncogene protein product
(a receptor for stem cell factor), and two independent mucin
molecules defined by their reactivity with mouse monoclonal
antibodies (mAb) M2A and TRA-1-60 respectively (Jacobson and
Norgaard-Pedersen, 1984; Bailey et al, 1986, 1991; Giwercman
et al, 1988, 1993; Strohmeyer et al, 1991; Rajpert-De Meyts and
Skakkebæk, 1994; Jørgensen et al, 1995; Rajpert-De Meyts et al,
1996). While the occasional observation of CIS during early
childhood is consistent with the notion that germ cell neoplasia
originates from a prenatal event (Skakkebæk et al, 1987), the
possibility that a genetic programme of oncofetal antigen
re-expression is induced upon post-natal transformation, giving
rise to CIS, remains open. The definition of biochemical markers
associated with germ cell neoplasia, and the availability of
reagents to examine archival collections of gonadal and extra-
gonadal tissues for the expression of these markers, would be
important for addressing the issues of latency between malignant
transformation, development of CIS and progression of CIS to an
invasive and potentially metastatic malignancy.
We have previously described mAb M2A which reacted with a
novel oncofetal membrane antigen present on fetal gonocytes, CIS
and primary testicular and extratesticular SE (Bailey et al, 1986,
1988, 1991; Giwercman et al, 1988; Jørgensen et al, 1995; Meng
et al, 1996). This antigen was absent in normal adult testis. M2A
antigen was found as well on dysgerminoma (DG) of the ovary,
the female counterpart of SE (Bailey et al, 1986). In addition to
its importance as a marker of progression of testicular neoplasia,
M2A antigen was also shown to be a developmental marker
of human Sertoli cells, present on immature Sertoli cells until
puberty, and lost during their transition to a mature adult
phenotype (Baumal et al, 1989).
In order to characterize this antigen, we have produced two
additional mAb, D1-26 (Ig2b) and D2-40 (IgG1), which have a
similar specificity to M2A, and, in addition, react with formalin
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Correspondence to:A Marksand B5-fixed tissues. Using this panel of mAb, we show that M2A
antigen is an O-linked sialoglycoprotein containing a simple
mucin-type carbohydrate epitope. Furthermore, since mAb M2A
does not react with specimens routinely fixed in formalin during
conventional preservation (Giwercman et al, 1991), we used mAb
D2-40 to stain sections of 69 archival blocks of TGCT, fixed in
formalin and embedded in paraffin, in order to extend our previous
results on the distribution of M2A antigen. We confirm uniform
membrane staining for M2A antigen in SE and CIS in the vicinity
of all TGCT. We also report focal staining for M2A antigen in EC,
IT and MT and YS, not previously detected in frozen sections
using mAb M2A (Bailey et al, 1991).
MATERIALS AND METHODS
Human tumour cell lines
The following human tumour cell lines were obtained from the
American Type Culture Collection (ATCC, Rockville, MD, USA):
ovary – Caov-3 (ATCC HTB-75) and SK-OV-3 (ATCC HTB-77);
bone – U-2 OS (ATCC HTB-96); bone marrow – KG-1a (ATCC
CCL-246.1); cervix – HeLa (ATCC CCL-2). The other cell
lines were generously provided by the following investigators:
ovary – HEY and HOC-7 (R Buick, University of Toronto),
and NIH:OVCAR-3 (RF Ozols, Fox Chase Cancer Center);
bladder – RT4, MGH-U3 and T-24 (Y Fradet, Laval University);
breast – MCF7 (R Buick), MDA-MB-468 (R Reilly, University of
Toronto); prostate – DU 145, PC-3 and LNCaP (T Brown,
University of Toronto); colon – Caco-2 (B Schimmer, University
of Toronto); pharynx – KB-3-1 (M Gottesman, National Institutes
of Health); melanoma – CaCL 74-36 and CaCL 78-1 (S-K Liao,
McMaster University), and WM 164 (J. Hainfeld, Brookhaven
National Laboratory). The cell lines were grown in monolayer
culture, except for KG-1a which was grown in suspension culture,
in minimal essential medium (MEM)-a (University of Toronto
Media Center, Toronto, ON, Canada) supplemented with 10%
heat-inactivated fetal bovine serum and L-glutamine (Gibco-BRL,
Gaithersburg, MD, USA) at 37°C, in a humidified 5% carbon
dioxide incubator.
Monoclonal antibodies
mAb M2A was produced by immunizing BALB/c mice with the
human ovarian epithelial carcinoma cell line HEY, as previously
described (Bailey et al, 1986), and D1-26 and D2-40 by
immunization with DG tissue resected from a female patient.
Hybridoma colonies were initially screened by enzyme-linked
immunosorbent assay (ELISA) for production of mouse IgG.
Hybridomas which produced IgG were screened directly for
immunoperoxidase staining of sections of formalin-fixed,
paraffin-embedded human SE and tonsil tissue. Hybridomas
which produced mAb reacting with SE, but not tonsil, were cloned
twice by limiting dilution. mAb were purified from ascitic fluid as
previously described (Sheldon et al, 1986), according to protocols
approved by the University of Toronto Animal Care Committee.
Determination of binding affinities of mAb to HEY cells
mAb D1-26 and D2-40 were labelled with 125I using N-bromo-
succinimide, as described previously (Buckman et al, 1992). mAb
M2A was labelled with 125I using the Bolton Hunter reagent,
N-succinimidyl-3-(4-hydroxyphenyl)-propionate (Amersham,
Oakville, ON, Canada) (Sheldon et al, 1986). The binding
affinities of the mAb to HEY cells were determined by two
methods: first, direct binding using a Scatchard plot, and second,
displacement of binding with increasing amounts of unlabelled
mAb, as previously described (Sheldon et al, 1986).
Western blotting
The cells were harvested by trypsinization and recovered by
centrifugation. The cell pellet was suspended at a concentration of
1–2 ´ 107 cells per ml in lysis buffer, 150 mM sodium chloride
(NaCl), 2 mM EDTA, 10 mM Tris-HCl, pH 8.0, containing 0.5%
Nonidet P-40 and 2 mM phenylmethylsulphonyl fluoride (PMSF;
Sigma, St Louis, MO, USA). After 20–30 min at 4°C, nuclei and
cellular debris were removed by centrifugation at 100 000 g for 30
min. The clarified supernatants were stored at –70°C until use.
Cell lysates of the following human cell lines, testicular terato-
carcinoma 577, Tera-1 and Tera-2, embryonal carcinoma 833 and
1618, ovarian teratocarcinoma PA-1, and glioblastoma T98G
(King et al, 1997), were kindly provided by Dr David Hogg
(University of Toronto). Aliquots containing 10 mg of protein were
analysed by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) in 10% slab gels under reducing condi-
tions. Western blotting was performed as previously described
(Bailey et al, 1986) except that the secondary antibody was the
peroxidase-conjugated F(ab´)2 fragment of goat anti-mouse IgG
antibody (Jackson Immuno Research, West Grove, PA, USA) used
at a 1:10 000 dilution. The blots were developed using enhanced
chemiluminescence (ECL, Amersham) and exposed to X-ray
film, or alternatively, by addition of the peroxidase substrate,
0.05% diaminobenzidine and 0.03% hydrogen peroxide (H2O2)
in phosphate-buffered saline (PBS).
Lectin affinity chromatography
HEY cell lysates were subjected to lectin affinity chromatography
on columns of concanavalin A, Ricinus communis agglutinin
and wheat germ agglutinin (WGA), eluted with 10% a-methyl
D-mannose, 10% D-galactose and 5% N-acetyl-D-glucosamine,
respectively, as described previously (Sutherland et al, 1988). The
presence of antigen reacting with mAb M2A in the bound and the
unbound fractions was assessed by Western blotting.
Antigen purification
The protocol for antigen purification was adapted from our previ-
ously published procedures (Sutherland et al, 1988), as follows. A
pellet of 2 ´ 109 HEY cells was suspended at 4°C in 25 ml of lysis
buffer and the cell lysate was prepared and stored at –70°C, as
described above. Following thawing, the cell lysate was applied
to a WGA-Sepharose 4B column, and the bound glycoprotein
fraction was eluted with 5% N-acetyl-D-glucosamine in lysis
buffer. The eluate was adjusted to 0.5 M NaCl, and subjected to
affinity chromatography on an immunoaffinity column, prepared
by cross-linking 10 mg of mAb M2A to 1 ml protein A-Sepharose
4B (Pharmacia, Baie d’Urfé, Quebec, Canada), as described
previously (Schneider et al, 1982). The column was washed
extensively, first with lysis buffer, then with the same buffer
containing 0.5% sodium deoxycholate and 0.5% SDS, and finally,
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(Boehringer Mannheim, Montreal, Quebec, Canada). The bound
antigen was eluted with 50mMdiethylamine, pH 11.5, containing
0.5% sodium deoxycholate, neutralized, concentrated and
analysed by SDS-PAGE in 8.5% slab gels under non-reducing
conditions. The protein bands were visualized by silver staining
using a commercial reagent (Bio-Rad, Mississauga, ON, Canada),
and the proteins reacting with mAb M2A were identified by
Western blotting.
Enzymatic digestion
Vibrio choleraneuraminidase, Pasteurella haemolyticaO-sialo-
glycoprotease and Bacillus cereusphosphatidylinositol phospholi-
pase C digestions were performed on whole cells and purified
antigen preparations. HEY cells were harvested by incubation in
PBS containing 20mMEDTA and resuspended at a concentration
of 1 ´107 per ml in PBS. Aliquots of 100ml were treated with
5 units of neuraminidase (BDH, Mississauga, ON, Canada), 5ml
of O-sialoglycoprotease (Cederlane, Hornby, ON, Canada), or 5ml
of phosphatidylinositol phospholipase C (Boehringer Mannheim),
for 30min at 37°C. The cells were washed, incubated with mAb
M2A, D1-26, or D2-40, followed by a fluorescein isothiocyanate-
conjugated F(ab´)2 fragment of goat anti-mouse Ig antibody, and
analysed by flow cytometry using a BD FACScan flow cytometer
(Becton Dickinson Immunocytometry Systems, San Jose, CA,
USA).
For treatment of partially purified antigen preparations, 10ml
(0.15mg) aliquots of the material eluted from the M2A-Sepharose
column were mixed with 1ml of 50mMsodium acetate buffer,
pH 5.4, and incubated with 0.1–2 units of neuraminidase, or 5ml
of O-sialoglycoprotease, for 15min to 3h at 37°C. The reactions
were stopped by boiling, and the treated aliquots were analysed by
Western blotting.
Analysis of 125I-labelled surface proteins
HEY cell surface proteins were labelled enzymatically with 125I
using lactoperoxidase, as described previously (Sutherland et al,
1988). Cell lysates were prepared as described above and immuno-
precipitated with mAb M2A and protein A-Sepharose beads
(Bailey et al, 1986). The 125I-labelled protein was released from the
immunoprecipitate by boiling for 5min in 100ml of sample buffer,
0.1MTris, pH 6.8, containing 10% glycerol and 2% SDS (non-
reduced protein), or of sample buffer containing 2% 2-mercapto-
ethanol (reduced protein), analysed by SDS-PAGE in 10%
polyacrylamide slab gels, and visualized by autoradiography, as
described previously (Sutherland et al, 1984).
Peanut agglutinin (PNA) chromatography of desialylated
immunoprecipitated protein was performed as described previ-
ously (Sutherland et al, 1988). The bound protein fraction was
analysed by SDS-PAGE and autoradiography.
For endoglycosidase digestion, the M2A antigen was eluted
from the gel, recovered by precipitation in 10% trichloroacetic
acid, divided into aliquots and digested with endoglycosidase
H (Eli Lilly, Indianapolis, IN, USA), peptide:N-glycosidase F
(Boehringer Mannheim), or sham-digested, as described previ-
ously (Sutherland et al, 1988). The treated protein was recovered
by precipitation in 10% trichloroacetic acid, and analysed by SDS-
PAGE and autoradiography.
Immunoperoxidase staining
Sections of archival collections of TGCT were obtained through
the Departments of Pathology of The Toronto Hospital, General
Division, and The Princess Margaret Hospital (Toronto, ON,
Canada). Immunoperoxidase staining of tissue sections was
performed as previously described (Bailey et al, 1986), with the
following modifications. Following incubation with hybridoma
supernatant or purified mAb (0.1–10mg ml–1), the sections were
incubated with biotinylated goat anti-mouse IgG antibody (Dako,
Carpinteria, CA, USA) at a 1:400 dilution followed by a horse-
radish peroxidase–avidin conjugate (Zymed, San Francisco, CA,
USA) at a 1:600 dilution. For colour development, the sections
were incubated with 0.05% diaminobenzidine and 0.03% H2O2
in PBS.
RESULTS
Production of mAb
Previously derived mAb M2A (IgG2a) was found to react with an
oncofetal testicular antigen in frozen sections and tissues
preserved in specialized fixatives, such as Stieve’s, Bouin’s and
Cleland’s reagents (Bailey et al, 1986; Giwercman et al, 1991). In
order to generate additional mAb for the biochemical characteriza-
tion of M2A antigen and its immunohistochemical detection in
archival specimens, we immunized mice with DG and screened
hybridoma supernatants for reactivity with sections of formalin-
fixed, paraffin-embedded SE. The underlying rationale for this
approach was twofold. First, it was expected to yield mAb directed
to antigens (including M2A antigen) shared by SE and DG, and
second, the direct screen with SE sections, as specified above,
would ensure that the selected mAb reacted with conventionally
preserved archival collections of tissues. In fact, two mAb, D1-26
(IgG2b) and D2–40 (IgG1), were successfully obtained using this
approach. Of the two, D2-40 reacted strongly with sections of
formalin-fixed, paraffin-embedded tissues, whereas D1-26 reacted
only weakly and inconsistently. Therefore, D2-40 was used for all
subsequent immunohistochemical staining of conventionally
preserved archival material. Both D1-26 and D2-40 reacted
strongly with tissues preserved in B5 fixative, a mercuric-type
reagent used to preserve the immunoreactivity of membrane
antigens. In contrast, mAb M2A did not react with tissues fixed
in formalin and only weakly with those fixed in B5.
Distribution of M2A antigen in fetal and neoplastic
testicular tissue
mAb D1-26 and D2-40 stained testicular SE fixed in B5 or
formalin, respectively, with strong accentuation of tumour cell
membranes (Figure 1 B,C), similar to that observed with M2A in
frozen sections (Figure 1A). Paranuclear staining was also seen
with mAb D2-40 (Figure 1D), indicative of the location of the
antigen in the paranuclear Golgi network where glycoproteins
are processed prior to their insertion into the membrane. D2-40
also stained sections of DG used for the original immunization
of mice (Figure 1E), EC (Figure 1F), CIS (Figure 1G) and fetal
testis (Figure 1H). There was no staining of uninvolved adult testis
in the vicinity of germ cell neoplasia (Figure 1G). There was
uniform membrane staining of tumour cells in SE, DG and CIS
(Figure 1 C,E,G), whereas staining in EC (Figure 1F) was focal in
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in the tumour cells which lined glands. D2-40 also stained primary
extratesticular SE, including pineal (2/2) and mediastinal (2/2).
This pattern of reactivity with testicular and extratesticular SE,
DG, CIS and fetal, but not adult, testis is the same as that
previously observed for mAb M2A in these tissues. In earlier
studies on a limited number of cryopreserved TGCT, mAb M2A
stained only CIS and SE, but not the other types of TGCT (Bailey
et al, 1991). Since mAb D2-40 reacted with formalin-fixed,
paraffin-embedded material, it was possible to extend these studies
by examining an archival collection of 69 TGCT for the distribu-
tion of M2A antigen. This collection included 41 pure TGCT
(35 SE, 5 EC and 1 IT), and 28 mixed germ cell tumours (MGCT).
The results of this survey are summarized in Table 1.
When the results obtained with pure TGCT and the corre-
sponding components of MGCT were combined, mAb D2-40 was
found to stain 98% of SE, 69% of EC, 29% of IT and MT, and 25%
of YS. There was no difference in staining between IT and MT.
572 A Marks et al
British Journal of Cancer (1999) 80(3/4), 569–578 © Cancer Research Campaign 1999
PostScript  Picture
CE2068F01  (Converted)-1
Figure 1 Immunoperoxidase staining of human tissue sections using monoclonal antibodies. (A) Testicular seminoma, snap-frozen, stained with M2A,
10 mg ml–1, ´ 190. (B) Testicular seminoma fixed in B5, stained with D1–26, 0.1 mg ml–1, ´ 190. (C–H) Tissues fixed in formalin, stained with D2-40, 0.1 mg ml–1.
(C) Testicular seminoma ´ 100. (D) Testicular seminoma showing paranuclear staining (arrows), ´ 150. (E) Ovarian dysgerminoma, ´ 190. (F) Embryonal
carcinoma, ´ 150. Mitotic figures are indicated by arrows. (G) Adult testis with CIS, showing positive staining of CIS (left) and absence of staining of uninvolved
tubule (right), ´ 120. (H) Fetal testis, ´ 190The only SE specimen that did not stain was an anaplastic SE, a
tumour type that has been previously noted to display an aberrant
pattern of antigen expression (Rajpert-De Meyts et al, 1996).
There was 100% staining of CIS in association with both semino-
matous and non-seminomatous TGCT. Whereas uniform
membrane staining was observed in SE and CIS, the staining in
EC, IT, MT and YS was focal in distribution, concentrated at the
lumenal surface of the membrane in the tumour cells which lined
glands. There was no staining of the uninvolved testicular tubules
in the vicinity of tumour cells in any of the specimens.
Reactivity of mAb with human tumour cell lines
The reactivity of the mAb with human tumour cell lines was
determined by Western blotting on cell lysates. A representative
Western blot is shown in Figure 2. In ovarian cancer HEY cell
lysates, M2A and D2-40 reacted with an Mr 40 000 antigen, and D1-
26 reacted with a doublet form of the antigen. In bladder cancer
MGH-U3 cells, M2A and D2-40, but not D1-26, reacted with a
slightly higher molecular weight form of the antigen. Neither M2A,
D2-40 nor D1-26 reacted with colon cancer Caco-2 cells. The reac-
tivity of mAb M2A, D2-40 and D1-26 with a panel of human cancer
cell lines, determined by Western blotting, is summarized in Table 2.
All three mAb reacted with three ovarian epithelial carcinoma cell
lines, HEY, Caov-3 and SK-OV-3, and the osteosarcoma cell line U-
2 OS. Among germ cell tumour cell lines, D2-40, but not M2A or
D1-26, reacted with the ovarian teratocarcinoma PA-1, the testicular
teratocarcinomas Tera-1 and Tera-2, and the embryonal carcinoma
833. There was no reactivity with the testicular teratocarcinoma 577
and the embryonal carcinoma 1618. In addition, M2A and D2-40,
but not D1-26, reacted with the bladder transitional cell carcinoma
cell lines MGH-U3 and RT-4. There was no reactivity with any of the
other cell lines derived from a wide spectrum of human cancers,
including ovary, bladder, breast, prostate, melanoma, cervix, colon,
pharynx, brain and bone marrow.
The binding affinities of M2A, D1-26 and D2-40 to HEY cells
were found to be 2 ´ 109 M–1, 2 ´ 108 M–1, and 2 ´ 108 M–1, respec-
tively, on the basis of Scratchard plot and binding displacement
analyses.
Antigen purification
Preliminary lectin affinity chromatography experiments indicated
that the antigen recognized by the mAb bound to WGA, but not to
concanavalin A or R. communis agglutinin. The antigen was puri-
fied from HEY cell lysates by sequential affinity chromatography
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Table 1 Reactivity of mAb D2-40 with testicular germ cell tumours
Specimen type Positive staininga
Pure germ cell tumour
SE 34/35
EC 1/5
IT and MT 0/1
MGCT component
SE 12/12
EC 17/21
IT and MT 5/16
YS 1/4
CC 0/2
CIS associated with:
SE 21/21
EC 1/1
MGCT 13/13
aRatios indicate number of specimens positively stained over the total
number examined.
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Figure 2 Western blot analysis of human cancer cell line lysates. Cell
lysates were prepared and analysed by Western blotting, using enhanced
chemiluminescence. The cell lines used to prepare the lysates are indicated
below the individual lanes: Caco-2 – colon, MGH-U3 – bladder, HEY – ovary.
The antibodies used for Western blotting are specified below each Western
blot. The position of the Mr 40k antigen is indicated
     
     
   
   
   
   
Figure 3 Electrophoretic analysis of purified antigen. The antigen
recognized by mAb M2A was purified from HEY cell lysate by sequential
affinity chromatography on WGA-Sepharose and M2A-Sepharose. The
fraction eluted from M2A-Sepharose was analysed by SDS-PAGE under
non-reducing conditions. (A) The proteins bands on the gel were visualized
by silver staining. (B) The protein bands reacting with mAb M2A were
demonstrated by Western blotting, using the peroxidase substrate
diaminobenzidine. The size of the molecular weight markers (Mr ´ 10–3)
is indicatedon WGA-Sepharose and M2A-Sepharose. The purified antigen
preparation contained four protein bands resolved on SDS-PAGE
and visualized by silver staining (Figure 3, lane A). The major
band at Mr 40 000 corresponded to a band stained by M2A on a
Western blot (Figure 3, lane B), representing the purified antigen
monomer. A higher molecular weight band at Mr 80 000 was also
visualized on a Western blot following staining with M2A, but not
when the secondary peroxidase-conjugated anti-mouse IgG
reagent alone was used. This band likely represents an antigen
dimer. Two additional contaminating high molecular weight bands
(Mr > 200 000) were also seen on the silver-stained gel, but not on
the Western blot (Figure 3).
Enzymatic digestion of purified antigen and whole cells
mAb M2A, D1-26 and D2-40 reacted with the purified Mr 40 000
antigen on Western blotting (Figure 4A, lane a). The reactivity of
the three mAb with the antigen was destroyed by prior treatment
with O-sialoglycoprotease (Figure 4A, lane b), indicating that the
antigen was an O-linked glycoprotein. The reactivity with M2A
and D1-26, but not D2-40, was also destroyed by treatment with
neuraminidase (Figure 4A, lane c), showing that a terminal sialic
acid residue in the epitope was required for reactivity with M2A
and D1-26.
Sequential digestion of the purified antigen preparation with
increasing amounts of neuraminidase demonstrated a slower
migration of the antigen with progressive removal of negatively
charged sialic acid residues (Figure 4B). This was seen using mAb
D2-40, which reacted with the desialylated antigen, and M2A,
which still reacted with the antigen after partial removal of the
sialic acid residues. In contrast, the reactivity of D1-26 with the
antigen was exquisitely sensitive to neuraminidase digestion, and
was lost after removal of sialic acid under the mildest conditions
used for digestion with the enzyme.
The above results were extended using HEY cell cultures by
performing enzymatic digestions on whole cells and detection of
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Figure 4 (A) Western blot analysis of purified antigen following enzymatic
digestion. The purified antigen preparation was analysed for reactivity with
mAb M2A, D1–26 and D2–40 by Western blotting, using enhanced
chemiluminescence, either untreated, or following digestion with
O-sialoglycoprotease (5 ml), or neuraminidase (2 units), for 3 h at 37°C. The
mAb used is indicated below each Western blot. Individual lanes were
treated as follows: (a) no treatment, (b) O-sialoglycoprotease,
(c) neuraminidase. (B) Western blot analysis of purified antigen following
digestion with increasing amounts of neuraminidase. The purified antigen
preparation was digested with increasing amounts of neuraminidase, and
analysed by Western blotting, using enhanced chemiluminescence. The mAb
used is indicated below each Western blot. The amounts of neuraminidase
used and the lengths of digestion in individual lanes were as follows: (a) 0;
(b) 0.1 unit, 15 min; (c) 0.1 unit,1 h; (d) 0.25 unit, 1 h; (e) 2 units, 1 h
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Figure 5 Flow cytometric analysis of HEY cells following enzymatic
digestion. HEY cells were digested with neuraminidase or O-
sialoglycoprotease, then stained by indirect immunofluorescence with mAb
M2A, D1–26, or D2–40 and analysed by flow cytometry, as indicated in the
individual panels. The shaded peaks represent control cells not subjected to
enzymatic digestion. Cells digested with O-sialoglycoprotease prior to
staining with the mAb are indicated by a thin solid line, and those digested
with neuraminidase by a thick solid linethe surface antigen by flow cytometry (Figure 5). Reactivity with
all three mAb was sensitive to digestion with O-sialoglycopro-
tease, although reactivity with D1-26 was less sensitive to diges-
tion with the enzyme than reactivity with M2A and D2-40
(Figure 5, thin solid line). On the other hand, reactivity with
D1-26 was most sensitive to digestion with neuraminidase,
reactivity with M2A was partially sensitive, and reactivity with
D2-40 was resistant to digestion with the enzyme (Figure 5, thick
solid line), confirming the results obtained using Western blot
analysis.
Reactivity of HEY cells with mAb M2A, as assessed by flow
cytometry, was not affected by treatment with phosphatidylinositol
phospholipase C, suggesting that the antigen was not anchored in
the membrane through a glycophosphatidylinositol linkage (data
not shown).
Analysis of 125I-labelled surface proteins
HEY cell surface proteins were labelled with 125I using lacto-
peroxidase, immunoprecipitated indirectly using mAb M2A and
protein A-Sepharose, dissociated from the immune complex under
reducing and non-reducing conditions, and analysed by SDS-
PAGE. A single Mr 40 000 band was visualized on the auto-
radiogram under both reducing and non-reducing conditions
(Figure 6A, lanes 1 and 2), corresponding to the monomeric form
of the antigen demonstrated previously by Western blotting
(Figures 2 and 3).
Two approaches were used to further characterize the carbohy-
drate structure of the antigen. In the first approach, the 125I-labelled
protein was dissociated from the immunoprecipitate, digested with
neuraminidase to remove sialic acid and incubated with PNA-
Sepharose beads. The protein bound to the lectin was dissociated
from the beads and analysed by SDS-PAGE. A single protein band
was visualized on the autoradiogram, migrating more slowly
(Mr 42 000) than the antigen immunoprecipitated without treat-
ment with neuraminidase (Figure 6A, lane 3).
In the second approach, the 125I-labelled protein was again
immunoprecipitated, dissociated from the immunoprecipitate and
subjected to SDS-PAGE as described above. The 125I-labelled
antigen was eluted from the polyacrylamide gel, incubated with
buffer alone, endoglycosidase H, or peptide:N-glycosidase F, and
re-analysed by SDS-PAGE (Figure 6B, lanes 6–8). The antigen
was not cleaved by digestion with either of these enzymes.
DISCUSSION
mAb M2A was found to react with a membrane antigen present on
fetal gonocytes, CIS and SE in testicular tissues preserved by
freezing or immersion in specialized fixatives (Bailey et al, 1986,
1991; Giwercman et al, 1988, 1991; Jørgensen et al, 1995). In
order to extend these results on the distribution of M2A antigen
and elucidate its biochemical structure, our experimental goal was
to produce mAb with a similar specificity to M2A which also
reacted with formalin-fixed, paraffin-embedded material.
Since M2A antigen was present on SE and its female counter-
part, DG, we used an experimental strategy to immunize mice with
DG, and to screen hybridomas, derived by fusion of splenocytes of
immunized mice, for production of mAb reacting with sections of
formalin-fixed, paraffin-embedded SE specimens. This strategy
was successful and two mAb were produced, D1-26 and D2-40,
which reacted with B5- and formalin-fixed, paraffin-embedded
tissues (Figure 1) with a specificity for fetal gonocytes, CIS,
testicular and extratesticular SE, and DG similar to that demon-
strated previously for mAb M2A (Bailey et al, 1986, 1991;
Jørgensen et al, 1995). The conclusive evidence that the three mAb
reacted with the same antigen was provided by purifying the
Mr 40 000 antigen from HEY cell lysates (Figure 3), and demon-
strating that the three mAb reacted with the same purified antigen
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Figure 6 Analysis of 125I-labelled surface proteins. HEY cell surface proteins were labelled with 125I, immunoprecipitated indirectly using mAb M2A and protein
A-Sepharose, dissociated from the immune complex under reducing and non-reducing conditions, and analysed by SDS-PAGE in 10% polyacrylamide slab gels
followed by autoradiography. (A) Lane 1 – non-reduced protein, lane 2 – reduced protein, lane 3 – protein dissociated from the immune complex, digested with
neuraminidase, bound to PNA-Sepharose beads, and eluted from PNA-Sepharose, lane 4 – molecular weight markers with Mr ´ 10–3 indicated. (B) Proteins
were immunoprecipitated and analysed by SDS-PAGE, as described for lane 1 above. The antigen band was eluted from the gel and divided into three aliquots
which were incubated with buffer alone, endoglycosidase H, or peptide:N-glycosidase F, recovered by precipitation in 10% trichloroacetic acid and re-analysed
by SDS-PAGE, lane 5 – molecular weight markers with Mr ´ 10–3 indicated, lane 6 – buffer alone, lane 7 – endoglycosidase H, lane 8 – peptide:N-glycosidase F(Figure 4). The success in selecting the hybridoma clones
producing mAb D1-26 and D2-40 by screening on SE following
immunization of mice with DG, a procedure completely different
from that used to produce mAb M2A by immunization with HEY
cells, suggests that the M2A antigen recognized by the three mAb
may be an immunodominant antigen on SE and DG.
M2A antigen was expressed in several human cancer cell lines,
including three ovarian epithelial carcinoma, one ovarian and
two testicular teratocarcinoma, one embryonal carcinoma, one
osteosarcoma and two bladder transitional carcinoma, but was
absent in many other cell lines derived from a variety of human
tumours (Table 2). At present, it is not known whether the expres-
sion of this antigen in a number of human cancer cell lines is
indicative of a lineage-specific marker shared by the cell line and
the tumour from which it was derived, or alternatively, whether the
presence of the antigen represents an aberrant expression of the
protein by the transformed cell line in vitro.
The presence of the antigen in the paranuclear Golgi apparatus
suggested that it was a glycoprotein (Figure 1D). This suggestion
was supported by variations in the molecular weight of the antigen
(Figure 2) and in its recognition by the individual mAb (Table 2)
in human cancer cell lines, likely reflecting differences in
glycosylation. In confirmation of this suggestion, reactivity with
the mAb was sensitive to digestion with O-sialoglycoprotease and
neuraminidase on the basis of Western blotting and flow cyto-
metric analyses (Figures 4 and 5), indicating that the antigen was
an O-linked sialoglycoprotein exposed on the cell surface. As
expected, removal of the negatively charged sialic acid residues
decreased the electrophoretic mobility of the antigen (Figure 4B).
Furthermore, the reactivity of the three mAb with their respective
complementary carbohydrate epitopes was differentially affected
by treatment with neuraminidase, D1-26 reactivity being exquisi-
tively sensitive to the removal of sialic acid, D2-40 reactivity
completely resistant, and M2A reactivity intermediate between the
other two (Figures 4 and 5).
We took advantage of the surface localization of the antigen to
label it with 125I using lactoperoxidase. This allowed a more direct
examination of its molecular structure in its usual membrane
location. Following immunoprecipitation of the 125I-labelled HEY
cell surface proteins with mAb M2A and SDS-PAGE, a single
protein band was visualized on the autoradiogram after dissocia-
tion of the immunoprecipitate under both reducing and non-
reducing conditions (Figure 6A). This suggests that the antigen
exists as a monomer and is not complexed with another membrane
protein. The dimeric form, previously observed in the purified
antigen preparation (Figure 3), likely is formed by aggregation
during the purification procedure. Alternatively, the dimeric form
in the membrane may not be accessible to iodination with
lactoperoxidase.
The  125I-labelled antigen was found to be resistant to digestion
with endoglycosidase H and peptide:N-glycosidase F, enzymes
which cleave asparagine-bonded oligomannosyl cores of precursor
N-linked glycoproteins and also complex-type N-linked glycans
characteristic of the fully processed cell surface glycoproteins
(Tarentino and Maley, 1974; Plummer et al, 1984; Sutherland et al,
1988) (Figure 6B). These results confirmed that the antigen was an
O-linked glycoprotein with no N-linked sugar groups. Absence of
N-linked sugar residues was also consistent with the lack of
binding of the antigen to concanavalin A, which binds specifically
to N-linked glycans (Wu et al, 1988), and our inability to radio-
label the antigen metabolically using the non-convertible
D-[2-3H]mannose precursor of N-linked sugars (unpublished
observations).
In order to characterize further the carbohydrate structure of the
antigen recognized by the mAb, we used affinity chromatography
on PNA-Sepharose. PNA binds to the structure Gal b(1–3)
GalNAc-0-Thr/Ser which is found only in O-linked glycoproteins
(Wu et al, 1988). When the 125I-labelled M2A immunoprecipitate
was digested with neuraminidase and fractionated on PNA-
Sepharose, the desialylated antigen was found to bind to the lectin.
Following elution from the lectin, the desialylated antigen
migrated more slowly in SDS-PAGE than the native antigen
(Figure 6A), as shown previously by Western blotting (Figure 4B).
Removal of sialic acid was essential for binding to PNA-
Sepharose, as the native antigen did not bind to the lectin (unpub-
lished observations). Similarly, failure of the native antigen to bind
to  R. communis agglutinin confirmed the absence of exposed
galactose or N-acetyl galactosamine residues, and binding to
WGA was also consistent with terminal sialylation (Peters et al,
1979). In addition, reactivity of the antigen with mAb M2A was
destroyed by treatment with periodate, a reaction that oxidizes the
terminal sialic acid residues of glycoproteins (unpublished
results).
The results of enzyme digestion and lectin fractionation suggest
that the antigen recognized by mAb M2A, D1-26 and D2-40
contains the simple mucin-type carbohydrate structure shown
below.
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Table 2 Reactivity of monoclonal antibodies with human cancer cell linesa
Cancer cell line
Ovary
HEY, Caov-3, SK-OV-3 lllb
NIH:OVCAR-3, HOC-7 l ll l
PA-1PA-1
Testis
Tera-1, Tera-2, 833
577, 1618 l ll l
Bone
U-2 OS l
Bladder
MGH-U3, RT-4, T-24 l l
Breast
MCF7, MDA-MB-468 l ll ll l
Prostate
DU145, PC-3, LNCaP l ll ll l
Melanoma
CaCL 78-1, WM 164 l ll l
CaCL 74-36 l l
Cervix
HeLa l l
Colon
Caco-2 l l
Pharynx
KB-3-1 l l
Brain
T98G l l
Bone marrow
KG-1a l l
aReactivity of mAb was determined on cell lysates by Western blotting.
bl Positive reactivity with M2A, D2-40, and D1-26; Positive reactivity with
D2-40, but not M2A or D1-26; ;  Positive reactivity with M2A and D2-40, but
not M2A or D1-26; l l   No reactivity with M2A, D2-40, or D1-26.SA a(2–3) Gal b(1–3) GalNAc-0-Thr/Ser
| a (2–6)
SA
where SA denotes sialic acid, Gal galactose and GalNAc N-acetyl
galactosamine.
The above carbohydrate structure is common in mucin-type
glycoproteins that are expressed widely on human normal cells
and tumours (Sutherland et al, 1988; Corraway and Hull, 1989;
Lesuffleur et al, 1994). Therefore, the remarkable specificity of
mAb M2A, D1-26 and D2-40 for fetal gonocytes, CIS and germ
cell tumours is likely based on the recognition by these mAb of a
mixed epitope whose structure is determined by the polypeptide
core together with the O-linked carbohydrate chain.
Two models have been proposed for the progression of testic-
ular CIS to invasive TGCT. In the independent progression model,
CIS can progress directly to SE and EC. In the linear progression
model, SE is an intermediate stage between CIS and EC. In both
models, EC is believed to be the precursor of IT and MT, YS and
CC. Our results do not distinguish between the two models, but
demonstrate a reprogramming in the expression of M2A antigen
during the transition of either CIS or SE to EC, and of EC to IT,
MT, YS and CC. Specifically, although there was uniform cell
membrane expression of M2A antigen in CIS and SE, there was
either no expression in EC, or focal membrane expression (Figure
1, Table 1). Furthermore, while this focal pattern of expression was
common to all non-seminomatous TGCT that expressed M2A
antigen, complete absence of expression was seen more frequently
in IT, MT, YS and CC than in EC (Table 1). This is compatible
with the notion that progressive loss of M2A antigen expression
occurs when EC becomes transformed into the other non-semino-
matous TGCT types.
M2A antigen belongs to the set of antigenic and molecular
markers that are useful to follow the transformation of fetal gono-
cytes to CIS and the progression of CIS to invasive TGCT. At
present, the elucidation of the carbohydrate epitope of M2A
antigen does not allow us to make any functional correlations
between the structure of the epitope and the above transitions.
However, such a correlation may be possible when additional
information about critical glycosylation reactions and mechanisms
of receptor activation influencing these becomes available. In
addition, the availability of mAb D2-40 which reacts with M2A
antigen in conventionally preserved surgical specimens, opens up
the way to examining archival collections of tissues for the expres-
sion of this antigen and further correlating this expression with
milestones in the origin and progression of germ cell neoplasia.
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